amphotericin B vs anidulafungin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of amphotericin B and anidulafungin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.5 Amphotericin B Liposome for Injection Administration of multiple doses of anidulafungin and liposomal amphotericin B to patients resulted in no significant alteration in the steady state pharmacokinetics of anidulafungin. No dosage adjustment of anidulafungin is needed when it is co-administered with liposomal amphotericin B [see Clinical Pharmacology (12.3) ] .
Ambisome, Fungizone
Eraxis
Amphotericin B liposome is an antifungal medicine. It fights serious fungal infections in your body.
Eraxis is an antifungal medicine. It treats certain Candida infections in your body.
This medicine treats fungal infections like aspergillosis, candidiasis, and cryptococcosis. It can also treat cryptococcal meningitis in people with HIV. It may also be used for visceral leishmaniasis, but this infection can return, especially in those with weak immune systems.
Eraxis treats candidemia and other Candida infections, like intra-abdominal abscesses and peritonitis. It can be used in adults and children 1 month and older. Eraxis also treats esophageal candidiasis (a Candida infection in the esophagus) in adults. However, Eraxis may not work as well for esophageal candidiasis, and the infection may come back.
Amphotericin B liposome belongs to a class of drugs called polyene antifungals. It works by binding to the membrane of the fungal cells. This binding disrupts the fungal cell membrane, causing the cell to die.
Eraxis belongs to a class of drugs called echinocandins. It works by stopping the growth of the fungus Candida. It does this by blocking a key part of the fungal cell wall.
- • Abdominal pain
- • Weakness
- • Back pain
- • Chills
- • Pain
- • Low potassium levels
- • Nausea
- • Diarrhea
- • Vomiting
- • Fever
- Pyrexia 972
- Condition Aggravated 841
- Febrile Neutropenia 650
- Acute Kidney Injury 625
- Sepsis 613
- Multiple Organ Dysfunction Syndrome 171
- Septic Shock 127
- Sepsis 115
- Pneumonia 94
- Pyrexia 90
This medicine is not interchangeable with other amphotericin B products. Different versions of amphotericin B act differently in the body. Make sure you always get the correct medicine.
Eraxis can cause liver problems. Your doctor should check your liver function while you are taking Eraxis. Allergic reactions, including shock, can happen. Tell your doctor right away if you have any signs of an allergic reaction, like rash, hives, flushing, itching, trouble breathing, or low blood pressure. Eraxis contains fructose. If you have hereditary fructose intolerance, you should not take Eraxis.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine will harm your unborn baby. Talk to your doctor about the risks and benefits of using this medicine during pregnancy or while breastfeeding.
Eraxis may harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Eraxis passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding while taking Eraxis.
Also Compare, Nearby Drugs
Compare amphotericin B with
Compare anidulafungin with
How to Read This amphotericin B vs anidulafungin Comparison
amphotericin B is classified in the Polyene Antifungal drug class, while anidulafungin sits within the Echinocandin Antifungal class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, amphotericin B has 3,701 submissions while anidulafungin has 597. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these medications do not interfere with each other's levels in the body. they do not change how the body processes the medicine.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for amphotericin B or anidulafungin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.